ZTS heads into its May 20 Q1 earnings report already carrying one of the most dramatic selloffs in its recent history — and the company's own board members are putting money on the line.
Three Zoetis directors bought shares in the open market this week, collectively spending around $886,000 at prices between $75 and $78. The Independent Chairman of the Board, the Independent Director, and a second Director all stepped in on May 11 and May 13. Net insider buying over the past 90 days runs to roughly $1.9 million. That kind of cluster buying, at the board level and at depressed prices, is the loudest insider signal Zoetis has sent in months — and it arrives just days before the print.
The backdrop is severe. The stock closed at $74.22 on Friday, down 39% over the past month and more than 40% year-to-date. The RSI-14 has collapsed to 13.65 — deeply oversold by almost any measure. The prior earnings report on May 7 triggered a single-day drop of 25.5% and a five-day loss of 32%. That move reset the price level entirely; the stock is now trading at a fraction of where most analysts still have their targets pegged.
Analyst targets reflect a world that no longer quite matches current prices. JPMorgan maintained its Overweight rating on May 8 but cut its target from $190 to $130, while UBS lowered its Neutral target to $99 from $130 on the same day. Citi initiated coverage in April at Buy with a $145 target. The mean price target across the Street is $128, implying roughly 73% upside from current levels — a gap so wide it reflects how quickly the stock moved below where most models were anchored. Bulls point to the durable strength of the companion animal bond, the breadth of Zoetis's product pipeline, and an estimated forward revenue base near $9.8 billion. Bears see a stock that failed to cushion a significant earnings miss, with ongoing risk from competitive pressure in dermatology and macro headwinds hitting the animal health end-market.
Options positioning reinforces the idea that the reflexive panic selling has already passed. The put/call ratio has dropped to 0.32, well below its 20-day average of 0.48 — the lowest demand for downside protection in weeks. Short interest is a relatively modest 3.2% of the free float, down from a peak near 4% in mid-April, and the cost to borrow is just 0.44%. Borrow availability remains ample. This is not a setup where aggressive short-sellers are pressing a crowded position into the report; the positioning data suggests the market has largely repriced the stock and stepped back.
The peer group adds context to the damage. Animal health and pharma names ELAN and PAHC each fell more than 14-16% on the week — suggesting sector-wide pressure rather than a Zoetis-specific collapse alone. MRK was the notable exception, roughly flat over the same period.
The May 20 print will test whether the guidance Zoetis offers can anchor a new, lower price range — or whether the board's open-market buying proves to have been premature.
See the live data behind this article on ORTEX.
Open ZTS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
